Literature DB >> 10612809

Comparative genomic hybridization analysis of hepatoblastomas.

J Hu1, M Wills, B A Baker, E J Perlman.   

Abstract

Prior cytogenetic analyses of hepatoblastomas have shown the most common recurring abnormalities to be trisomy for chromosomes 2 and 20, and a recurrent translocation involving chromosomes 1 and 4 identified in a minority of cases. Four cases have shown double minute chromosomes, which provide cytogenetic evidence for gene amplification, although no particular genes or genetic regions have been shown to be amplified. To further investigate the cytogenetic changes involved in the pathogenesis and progression of hepatoblastoma, this study analyzes 10 tumors by comparative genomic hybridization. Regions of relative gain or loss were found in nine tumors. The most common recurrent abnormalities were gain of the long arm of chromosome 1 (six tumors), gain of chromosomes 2 (seven tumors), 17 (four tumors), and 20 (three tumors), and loss of chromosomes 4 and 11 (two tumors each). Four cases showed restricted regions of high-level gain at 1q32 or 2q24, regions that have previously been reported to be amplified in other tumors, but not in hepatoblastomas. A specific amplified gene has yet to be identified at these loci, although candidate genes have been proposed and may offer targets for future studies. Genes Chromosomes Cancer 27:196-201, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10612809     DOI: 10.1002/(sici)1098-2264(200002)27:2<196::aid-gcc12>3.0.co;2-d

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.

Authors:  R G Weber; T Pietsch; D von Schweinitz; P Lichter
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  [Current status of diagnosis and treatment of hepatoblastoma].

Authors:  Purificación García-Miguel; Manuel López Santamaría
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

3.  Gene expression profiling of human hepatoblastoma using archived formalin-fixed and paraffin-embedded tissues.

Authors:  Eun Shin; Kyoung-Bun Lee; Soo-Young Park; Soo-Hee Kim; Han-Suk Ryu; Young-Nyun Park; Eunsil Yu; Ja-June Jang
Journal:  Virchows Arch       Date:  2011-03-03       Impact factor: 4.064

4.  hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors.

Authors:  Xing Fan; Yunyue Wang; John Kratz; Dan J Brat; Yves Robitaille; Albert Moghrabi; Elizabeth J Perlman; Chi V Dang; Peter C Burger; Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

5.  Current awareness.

Authors:  R Drysdale; L Bayraktaroglu
Journal:  Yeast       Date:  2000-06-30       Impact factor: 3.239

6.  Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas.

Authors:  S G Gray; S Kytölä; T Matsunaga; C Larsson; T J Ekström
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

7.  Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: cytogenetic and comparative genomic hybridization analysis.

Authors:  K Kumon; H Kobayashi; T Namiki; Y Tsunematsu; J Miyauchi; A Kikuta; Y Horikoshi; Y Komada; Y Hatae; H Eguchi; Y Kaneko
Journal:  Jpn J Cancer Res       Date:  2001-08

8.  Copy Number Alterations in Hepatoblastoma: Literature Review and a Brazilian Cohort Analysis Highlight New Biological Pathways.

Authors:  Juliana Sobral Barros; Talita Ferreira Marques Aguiar; Silvia Souza Costa; Maria Prates Rivas; Monica Cypriano; Silvia Regina Caminada Toledo; Estela Maria Novak; Vicente Odone; Lilian Maria Cristofani; Dirce Maria Carraro; Isabela Werneck da Cunha; Cecília Maria Lima Costa; Angela M Vianna-Morgante; Carla Rosenberg; Ana Cristina Victorino Krepischi
Journal:  Front Oncol       Date:  2021-12-08       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.